HAVANA, Cuba, Aug 27 (ACN) The Pan American Health Organization (PAHO) and the World Health Organization (WHO), in conjunction with the United Nations in Cuba, value the development of a vaccine in the region as very favorable and join forces for financial support.
Cuba is one of the first 14 countries to advance a vaccine candidate against COVID-19 to the clinical trials phase, and SOBERANA 01, name given to the vaccine, deserves the support of national and international institutions, which see in it a hopeful step in the fight against the new coronavirus.
After injecting the first 20 volunteers for the clinical trial of the vaccine candidate, Dagmar Garcia, Director of Research at the Finlay Vaccine Institute, leading center of the study, reported zero serious adverse events.
The Information Note No. 1 of the SOBERANA 01 Clinical Trial stated that the only adverse effect recorded was mild pain at the injection site, which is a side effect, common to all vaccines.
The first safety report will be delivered on August 31 to the authorities of the Center for State Control of Drugs, Equipment and Medical Devices, and later, the trial will begin with the rest of the expected subjects, belonging to the age group between 60 -80 years, according to a statement released on the Finlay Institute website.
So far, the schedule foreseen in this clinical trial is being met, where safety, reactogenicity and immunogenicity are evaluated in healthy adults between 19 and 80 years of age.